Agenus Inc. (“Agenus”) (NASDAQ: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced that its Annual Shareholders Meeting will begin at 10:30 a.m. ET on June 11, 2024, and will be conducted in a virtual format only. Registration for attendees will start at 10:15 a.m. ET.
To participate in the Annual Shareholders Meeting, shareholders should visit www.virtualshareholdermeeting.com/AGEN2024 and enter the 16-digit control number found in their proxy materials. Guests may also access the Annual Shareholders Meeting, but in listen-only mode. No control number is required for guests.
Webcast Information:
Date: Tuesday, June 11, 2024
Time: 10:30 a.m. ET
A live webcast and replay will be accessible on the Company’s website at https://investor.agenusbio.com/events-and-presentations and at www.virtualshareholdermeeting.com/AGEN2024.
About Agenus
Agenus is a leading immuno-oncology company targeting cancer and infectious diseases with a comprehensive pipeline of immunological agents. The company’s mission is to expand patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics) and adjuvants (through SaponiQx). Agenus is headquartered in Lexington, MA. For more information, visit www.agenusbio.com or @agenus_bio. Information that may be important to investors will be routinely posted on our website and social media channels.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240604262147/en/
Contacts
Investor
917-362-1370
investor@agenusbio.com
Media
612-839-6748
communications@agenusbio.com
